Efficacy and safety of novel immune checkpoint inhibitor‐based combinations versus chemotherapy as first‐line treatment for patients with extensive‐stage small cell lung cancer: A network meta‐analysis

杜瓦卢马布 医学 阿替唑单抗 肿瘤科 内科学 养生 化疗 肺癌 彭布罗利珠单抗 不利影响 危险系数 易普利姆玛 银耳霉素 癌症 免疫疗法 置信区间
作者
Chenguang Yang,Tiantian Xuan,Qiang Gong,Xin Dai,Chengjun Wang,Rongyu Zhang,Wen Zhang,J Wang,Weiming Yue,Jisheng Li
出处
期刊:Thoracic Cancer [Wiley]
标识
DOI:10.1111/1759-7714.15310
摘要

Patients with extensive-stage small cell lung cancer (ES-SCLC) have an exceptionally poor prognosis and immune checkpoint inhibitors (ICIs) combined with etoposide-platinum is recommended as standard first-line therapy. However, which combination pattern is the best still remains unknown. This network meta-analysis was performed to compare the efficacy and safety of currently available patterns including an antiangiogenic agent containing regimen and probed into the most appropriate therapy for patients.Hazard ratios (HRs) and odds ratios (ORs) were generated using R software. The outcomes of overall survival (OS), progression-free survival (PFS), objective response rate (ORR), and adverse events of grade 3 or higher (grade ≥ 3 adverse events [AEs]) were analyzed.A total of 10 randomized controlled trials (RCTs) involving 5544 patients were included for analysis. Drug combination patterns included adebrelimab, atezolizumab, durvalumab, durvalumab plus tremelimumab, ipilimumab, pembrolizumab, serplulimab, benmelstobart plus anlotinib, tislelizumab, tiragolumab plus atezolizumab and toripalimab in combination with chemotherapy. The novel antiangiogenic agent containing regimen benmelstobart + anlotinib + chemotherapy showed the highest possibility to present the best PFS and OS versus chemotherapy. Compared with ICI plus chemotherapy, it also achieved significantly better PFS and presented a tendency of OS benefit. As for safety and toxicity, patients treated with benmelstobart + anlotinib + chemotherapy and durvalumab + tremelimumab + chemotherapy suffered a higher likelihood of more grade ≥ 3 AEs without unexpected AEs.PD-1/PD-L1 inhibitors-based combinations are associated with significant improvement in both PFS and OS for treatment-naïve ES-SCLC patients. Benmelstobart plus anlotinib with chemotherapy (CT) yielded better survival benefit versus CT alone or other ICIs + CT with caution for more adverse effects along with the addition of an antiangiogenic agent.

科研通智能强力驱动
Strongly Powered by AbleSci AI
科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
xiongmao2528发布了新的文献求助10
2秒前
健忘的从灵完成签到,获得积分10
2秒前
伶俐书蝶完成签到 ,获得积分10
3秒前
苹果大侠完成签到 ,获得积分10
3秒前
驴教授的拉磨之旅完成签到,获得积分10
6秒前
威武幼荷完成签到 ,获得积分10
7秒前
mufulee完成签到,获得积分10
7秒前
molihuakai的应助被灶鲜森采纳,获得10
8秒前
明理的踏歌完成签到,获得积分0
9秒前
Qps完成签到 ,获得积分10
9秒前
包容雁菡完成签到,获得积分10
9秒前
852的应助被ice采纳,获得10
13秒前
花花子完成签到 ,获得积分10
16秒前
17秒前
369ninja的应助被风格采纳,获得30
19秒前
布曲完成签到 ,获得积分10
20秒前
YZ完成签到 ,获得积分10
20秒前
灶鲜森发布了新的文献求助10
22秒前
lili完成签到 ,获得积分10
28秒前
清脆代真完成签到,获得积分10
28秒前
Hanoi347完成签到,获得积分0
30秒前
gangxiaxuan完成签到,获得积分10
30秒前
ironsilica完成签到,获得积分10
32秒前
俏皮的绮波完成签到,获得积分10
35秒前
地动完成签到 ,获得积分10
41秒前
于生有你完成签到,获得积分10
44秒前
Ava的应助被科研通管家采纳,获得10
45秒前
老迟到的断秋完成签到,获得积分10
45秒前
YifanWang的应助被科研通管家采纳,获得10
45秒前
彩色的冥茗完成签到,获得积分10
48秒前
49秒前
wang完成签到,获得积分10
51秒前
zxcvbnmgx完成签到 ,获得积分10
52秒前
yulian完成签到,获得积分10
53秒前
冷傲新柔发布了新的文献求助10
55秒前
科研通AI6.4的应助被cfw采纳,获得10
57秒前
kyt_vip完成签到,获得积分10
58秒前
sun完成签到 ,获得积分10
59秒前
wangji_2017完成签到,获得积分10
59秒前
大模型的应助被黑熊精采纳,获得10
1分钟前
高分求助中
(应助此贴封号)【重要!!请各用户(尤其是新用户)详细阅读】【科研通的精品贴汇总】 10000
拉伸高分子熔体中缠结行为的模拟和小角中子散射研究 1700
The World Atlas of Wine 9th edition 1000
奈特基础组织学:配套组织病理学(第4版)(Netter's Essential Histology With Correlated Histopathology) 800
John McDowells Bildungstheorie 800
Social Psychology in the Real World 600
八旗制度の研究 600
热门求助领域 (近24小时)
化学 材料科学 医学 生物 纳米技术 计算机科学 工程类 有机化学 化学工程 生物化学 物理 复合材料 内科学 催化作用 光电子学 人工智能 细胞生物学 无机化学 物理化学 数学
热门帖子
关注 科研通微信公众号,转发送积分 8180053
求助须知:如何正确求助?哪些是违规求助? 9570224
关于积分的说明 21808682
捐赠科研通 7776054
什么是DOI,文献DOI怎么找? 3433261
关于科研通互助平台的介绍 2557425
邀请新用户注册赠送积分活动 2479012